Abstract:Acquired drug resistance is a major cause of failure of cancer chemotherapy. Rapidly dividing cancer cells quickly evolve DNA mutations to bypass any single drug targeted metabolic pathway. Several drugs targeting different cancer biomarkers, can be used in combination, to target multiple biomarkers simultaneously, to reduce the tumor's ability to provide sufficient mutations to evade the simultaneous attack. We hypothesize a new cancer treatment paradigm to overwhelm the ability of the cancer to rapidly evolve sufficient drug resistant pathways to survive. Simultaneous administration of a large array of hundreds of different drugs targeting cancer specific proteins at many sites on these proteins will overwhelm the ability of the cancer cells to survive by simultaneously developing pathways around the effects of all these drugs. We propose that hundreds of small molecule oligonucleotide aptamers be used to selectively bind the surface proteins of cancer cells and hinder their function. Therapeutic radionuclides added to the selected array of aptamers will enhance the cancer treatment. Unlike single drugs which must target a unique focus on a cancer specific protein, radiolabeled aptamers can target anywhere on a cancer specific protein to exert their effects. Toxicity of cancer chemotherapy, another major cause of cancer chemotherapy failure, is caused by binding of chemotherapeutic drugs to components present in normal cells. To reduce therapeutic toxicity, aptamers which bind normal cell proteins can be subtracted from the array of aptamers binding cancer cell proteins. Libraries of hundreds of million inexpensive commercially obtained random aptamers which bind proteins extracted from human cancer tissue, can be selected in vitro. Although the cancer proteins will not retain all of their in vivo configurations, the use of a large array of aptamers will assure that many aptamers will bind many of the in vitro sites that retain their configuration in vivo. Subtraction of aptamers binding to normal cell proteins to reduce toxicity will also remove aptamers binding normal proteins in the cancer cells. The final selected array of hundreds of aptamers will represent aptamers binding only the cancer specific molecules. As proof of principle of our hypothesis, proteins extracted from tumors that develop after implanation of cancer cells in xenogenic mice can be used as targets for multiple rounds of aptamer selection, reimplanation and reselection. To reduce toxicity, aptamers binding to proteins extracted from a collection of many different normal mouse tissues can be subtracted from the array of selected aptamers.

Structure-Guided and Phage-Assisted Evolution of Therapeutic Antibodies to Reverse On-Target Point Mutation-Mediated Resistance

Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance

Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

Computational Engineering of a Therapeutic Antibody to Inhibit Multiple Mutants of HER2 Without Compromising Inhibition of the Canonical HER2

Improving antibodies by evolution and engineering

Directed Evolution of Therapeutic Antibodies Targeting Glycosylation in Cancer

Phenotypic switching as a non-genetic mechanism of resistance predicts antibody therapy regimens

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis

Abstract 544: Reverse engineering strategy for new targets identification

Computational Design of an Epitope-Specific Keap1 Binding Antibody Using Hotspot Residues Grafting and CDR Loop Swapping

Abstract PL6-2: Antibody-initiated cancer immunotherapy

Broad RTK-targeted Therapy Overcomes Molecular Heterogeneity-Driven Resistance to Cetuximab Via Vectored Immunoprophylaxis in Colorectal Cancer

Antibody-targeted T cells and natural killer cells for cancer immunotherapy

Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation

EGFR degraders in non-small-cell lung cancer: Breakthrough and unresolved issue

Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering

New approach to acquired drug resistance and toxicity in cancer chemotherapy

Using Antagonistic Pleiotropy to Design a Chemotherapy-Induced Evolutionary Trap to Target Drug Resistance in Cancer

Targeted Degradation of ABCG2 for Reversing Multidrug Resistance by Hypervalent Bispecific Gold Nanoparticle-Anchored Aptamer Chimeras

Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation